Aytu BioScience Inc Aktie News

Der Nettoumsatz im vierten Quartal des Geschäftsjahres 2026 stieg um 6,4 % auf 16,1 Mio. USD gegenüber 15,1 Mio. USD im Vorjahresquartal Das bereinigte EBITDA des vierten Quartals des Geschäftsjahres 2026 betrug 0,5 Mio. USD EXXUA-Umsatz in Höhe von 6,6 Mio. USD im Geschäftsjahr 2026, darunter 3,9 Mio. USD im vierten Quartal, nach vollständiger Markteinführung im dritten Quartal des Geschäftsja...

DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vega...

DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Co...

EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates Total net revenue of $12.4 million Adjusted EBITDA1 of $(2.8) million, which includes EXXUA ™ (gepirone) extended-release tablets ( " EXXUA " ) launch investments as the Company enters the over $22 billion United States prescripti...

DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2...